Elevance Health (ELV)
NYSE Market Closed
Elevance Health, Inc. is one of the largest managed healthcare companies in the United States, serving tens of millions of medical members through a mix of employer-sponsored, individual, Medicaid, and Medicare-related plans. The company is best known for its health benefits business, but it also operates a growing services platform that includes pharmacy benefit management, care delivery, analytics, and other healthcare support functions.
A defining feature of Elevance Health is its position within the Blue Cross Blue Shield system. The company is the licensed Blue Cross Blue Shield operator in 14 states, making it the largest single provider of BCBS-branded coverage in the country. That brand presence gives Elevance a strong position in many local insurance markets, particularly among employers and government-sponsored programmes.
Elevance has expanded beyond its traditional commercial insurance base through acquisitions and investment in public-sector healthcare. The 2012 purchase of Amerigroup strengthened its Medicaid capabilities, while later deals, including MMM in Puerto Rico, broadened its Medicare Advantage and government-programme reach. These businesses expose the company to long-term demand from ageing populations and public healthcare funding, while also requiring close management of regulation, reimbursement, and medical cost trends.
The company’s Carelon segment reflects Elevance’s shift toward a more integrated healthcare model. Through pharmacy services, behavioural health, payment integrity, and care management capabilities, Elevance seeks to capture more of the healthcare value chain and improve outcomes for members. For investors, ELV represents a major US health insurer with scale, a distinctive Blue Cross Blue Shield footprint, and increasing exposure to healthcare services beyond traditional insurance underwriting.
Last updated
- Market Cap
- 90.24B
- P/E
- 17.21
- P/FCF
- 13.99
- P/S
- 0.45
- Enterprise Value
- 112.42B
- Sector
- Financials
- Industry
- Hospital and Medical Service Plans
- Address
- 220 VIRGINIA AVENUE, INDIANAPOLIS, IN, 46204
ELV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Elevance Health, Inc.
Elevance Health, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3 Beaten-Down Stocks Ready to Kick Off 2026 on the Front Foot
Elevance Health: Solid Q3 Results Support Confident Full-Year Guidance
Important Notice to Long-Term Shareholders of Elevance Health, Inc. (NYSE: ELV); Humana Inc. (NYSE: HUM); Maison Solutions Inc. (NASDAQ: MSS); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Elevance Health Inc. (NYSE: ELV); Fluor Corporation (NYSE: FLR); and Fly-E Group, Inc. (NASDAQ: FLYE): Grabar Law Office is Investigating Claims on Your Behalf
Top Technology Executives Recognized at the 2025 Carolina CIO ORBIE Awards
Elevance Stock Faces Headwinds After Q2 EPS Miss and Margin Compression
ELEVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Elevance Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Why Centene Stock Dropped 40% — And Whether It's a Buy Now
ELV DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Elevance Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 11 Deadline in Securities Class Action – ELV
Elevance Health (NYSE: ELV) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
ELV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ELV Investors Have the Opportunity to Lead the Elevance Health Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
ELV INVESTOR DEADLINE: Elevance Health, Inc. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 11 Court Deadline (NYSE:ELV)
ELV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Fortrea Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTRE
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV
ELV FRAUD ALERT: Elevance Health, Inc. Investors are Reminded of Ongoing Securities Fraud Class Action -- Contact BFA Law by July 11 Legal Deadline (NYSE:ELV)
ELV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 90.24B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 112.42B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 17.21
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.06
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.45
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 12.27
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.56
- EPS
- 24.14
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 1.68%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 13.99
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 11.87
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 6.45B
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 11.94%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 4.17%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.73
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 4.07
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 4.07
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.21
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.7M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 415.53
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 50.18B | 49.75B | 50.71B | 49.78B | 48.89B |
| Gross profit | 14.57B | 11.68B | 12.57B | 13.07B | 13.58B |
| Operating income | 2.66B | 581M | 1.76B | 2.63B | 3.14B |
| EBITDA | 3.02B | 987M | 2.14B | 3.01B | 3.51B |
| Net income | 1.76B | 547M | 1.19B | 1.74B | 2.18B |
| Basic EPS | 8.03 | 2.55 | 5.32 | 7.72 | 9.64 |
| Diluted EPS | 8 | 2.54 | 5.32 | 7.72 | 9.61 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 125.83B | 121.49B | 122.75B | 121.94B | 119.72B |
| Total liabilities | 81.79B | 77.47B | 78.67B | 78.09B | 77.1B |
| Total equity | 44.04B | 44.03B | 44.08B | 43.85B | 42.62B |
| Cash & equivalents | 9.66B | 9.49B | 8.71B | 8.56B | 7.5B |
| Current assets | 32.45B | 31.03B | 31.06B | 31.69B | 29.68B |
| Current liabilities | 7.97B | 8.82B | 7.92B | 8.84B | 8.77B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 4.33B | 84M | 1.14B | 2.05B | 1.02B |
| Investing cash flow | -1.64B | 464M | -1.22B | -687M | 103M |
| Financing cash flow | -2.52B | 236M | 243M | -308M | -1.91B |
| Change in cash | 166M | 778M | 153M | 1.06B | -788M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 144 — Elevance Health, Inc. | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 8-K — Elevance Health, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — HAY LEWIS III | View Filing | |
| form 4 | Form 4 — COLLIS STEVEN H | View Filing | |
| form 4 | Form 4 — PERU RAMIRO G | View Filing | |
| form 4 | Form 4 — Schneider Ryan M. | View Filing | |
| form 4 | Form 4 — SCHULMAN AMY W | View Filing | |
| form 4 | Form 4 — Dixon Robert L JR | View Filing | |
| form 4 | Form 4 — DeVore Susan D. | View Filing | |
| form 4 | Form 4 — STRABLE-SOETHOUT DEANNA D | View Filing | |
| form 4 | Form 4 — Neri Antonio F | View Filing | |
| form 4 | Form 4 — Jallal Bahija | View Filing | |
| edgar index | SCHEDULE 13G — Elevance Health, Inc. | View Filing | |
| edgar index | 8-K — Elevance Health, Inc. | View Filing | |
| edgar index | 10-Q — Elevance Health, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | PX14A6G — Elevance Health, Inc. | View Filing | |
| edgar index | DEF 14A — Elevance Health, Inc. | View Filing | |
| edgar index | DEFA14A — Elevance Health, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| form 4 | Form 4 — SCHULMAN AMY W | View Filing | |
| edgar index | 8-K — Elevance Health, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 144 — Elevance Health, Inc. | View Filing | |
| form 4 | Form 4 — Kendrick Charles Morgan JR | View Filing | |
| form 4 | Form 4 — COLLIS STEVEN H | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| edgar index | 4 — Elevance Health, Inc. | View Filing | |
| form 4 | Form 4 — BOUDREAUX GAIL | View Filing | |
| form 4 | Form 4 — Haytaian Peter D | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| form 4 | Form 4 — LAVU RATNAKAR | View Filing | |
| form 4 | Form 4 — Norwood Felicia F | View Filing | |
| form 4 | Form 4 — Kaye Mark | View Filing | |
| form 4 | Form 4 — Kendrick Charles Morgan JR | View Filing | |
| form 4 | Form 4 — Craig Ryan R | View Filing | |
| form 4 | Form 4 — Wessling Erin M | View Filing | |
| edgar index | 8-K — Elevance Health, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — BOUDREAUX GAIL | View Filing | |
| form 4 | Form 4 — BOUDREAUX GAIL | View Filing | |
| form 4 | Form 4 — BOUDREAUX GAIL | View Filing | |
| form 4 | Form 4 — BOUDREAUX GAIL | View Filing | |
| form 4 | Form 4 — BOUDREAUX GAIL | View Filing | |
| form 4 | Form 4 — Haytaian Peter D | View Filing | |
| form 4 | Form 4 — Haytaian Peter D | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing | |
| form 4 | Form 4 — Penczek Ronald W | View Filing |